{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T21:01:54Z","timestamp":1777323714664,"version":"3.51.4"},"reference-count":118,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T00:00:00Z","timestamp":1575244800000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000921","name":"European Cooperation in Science and Technology","doi-asserted-by":"publisher","award":["COST CM1406"],"award-info":[{"award-number":["COST CM1406"]}],"id":[{"id":"10.13039\/501100000921","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The flexibility of the epigenome has generated an enticing argument to explore its reversion through pharmacological treatments as a strategy to ameliorate disease phenotypes. All three families of epigenetic proteins\u2014readers, writers, and erasers\u2014are druggable targets that can be addressed through small-molecule inhibitors. At present, a few drugs targeting epigenetic enzymes as well as analogues of epigenetic modifications have been introduced into the clinic use (e.g. to treat haematological malignancies), and a wide range of epigenetic-based drugs are undergoing clinical trials. Here, we describe the timeline of epigenetic drug discovery and development beginning with the early design based solely on phenotypic observations to the state-of-the-art rational epigenetic drug discovery using validated targets. Finally, we will highlight some of the major aspects that need further research and discuss the challenges that need to be overcome to implement epigenetic drug discovery into clinical management of human disorders. To turn into reality, researchers from various disciplines (chemists, biologists, clinicians) need to work together to optimise the drug engineering, read-out assays, and clinical trial design.<\/jats:p>","DOI":"10.1186\/s13148-019-0776-0","type":"journal-article","created":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T15:09:09Z","timestamp":1575299349000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":305,"title":["The timeline of epigenetic drug discovery: from reality to dreams"],"prefix":"10.1186","volume":"11","author":[{"given":"A.","family":"Ganesan","sequence":"first","affiliation":[]},{"given":"Paola B.","family":"Arimondo","sequence":"additional","affiliation":[]},{"given":"Marianne G.","family":"Rots","sequence":"additional","affiliation":[]},{"given":"Carmen","family":"Jeronimo","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6750-0400","authenticated-orcid":false,"given":"Mar\u00eda","family":"Berdasco","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2019,12,2]]},"reference":[{"key":"776_CR1","first-page":"18","volume":"1","author":"CH Waddington","year":"1942","unstructured":"Waddington CH. The epigenotype. Endeavour. 1942;1:18\u201320.","journal-title":"Endeavour."},{"key":"776_CR2","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1534\/genetics.114.173492","volume":"199","author":"C Deans","year":"2015","unstructured":"Deans C, Maggert KA. What do you mean, \u201cepigenetic\u201d? Genetics. 2015;199:887\u201396.","journal-title":"Genetics."},{"key":"776_CR3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejphar.2018.08.021","volume":"837","author":"S Biswas","year":"2018","unstructured":"Biswas S, Rao CM. Epigenetic tools (The Writers, The Readers and The Erasers) and their implications in cancer therapy. Eur J Pharmacol. 2018;837:8\u201324.","journal-title":"Eur J Pharmacol."},{"key":"776_CR4","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/nrc3130","volume":"11","author":"SB Baylin","year":"2011","unstructured":"Baylin SB, Jones PA. A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer. 2011;11:726\u201334 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21941284.","journal-title":"Nat Rev Cancer"},{"key":"776_CR5","doi-asserted-by":"crossref","unstructured":"Berdasco M, Esteller M. Clinical epigenetics: seizing opportunities for translation. Nat Rev Genet. 2018; Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30479381.","DOI":"10.1038\/s41576-018-0074-2"},{"key":"776_CR6","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s40291-017-0259-y","volume":"21","author":"YN Lamb","year":"2017","unstructured":"Lamb YN, Dhillon S. Epi proColon\u00ae 2.0\u2009CE: A blood-based screening test for colorectal cancer. Mol Diagn Ther. 2017;21:225\u201332.","journal-title":"Mol Diagn Ther"},{"key":"776_CR7","first-page":"RRN1220","volume":"3","author":"RM Ned","year":"2011","unstructured":"Ned RM, Melillo S, Marrone M. Fecal DNA testing for colorectal cancer screening: the ColoSure\u2122 test. PLoS Curr. 2011;3:RRN1220 Available from: http:\/\/currents.plos.org\/genomictests\/article\/fecal-dna-testing-for-colorectal-cancer-od1hzthyodr3-1.","journal-title":"PLoS Curr"},{"key":"776_CR8","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13148-017-0365-z","volume":"9","author":"R Delgado-Morales","year":"2017","unstructured":"Delgado-Morales R, Ag\u00eds-Balboa RC, Esteller M, Berdasco M. Epigenetic mechanisms during ageing and neurogenesis as novel therapeutic avenues in human brain disorders. Clin Epigenetics. 2017;9:67 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28670349.","journal-title":"Clin Epigenetics"},{"key":"776_CR9","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.4161\/15592294.2014.983367","volume":"9","author":"S Mithraprabhu","year":"2014","unstructured":"Mithraprabhu S, Kalff A, Chow A, Khong T, Spencer A. Dysregulated class I histone deacetylases are indicators of poor prognosis in multiple myeloma. Epigenetics. 2014;9:1511\u201320.","journal-title":"Epigenetics."},{"key":"776_CR10","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3389\/fonc.2019.00194","volume":"9","author":"M Han","year":"2019","unstructured":"Han M, Jia L, Lv W, Wang L, Cui W. Epigenetic enzyme mutations: role in tumorigenesis and molecular inhibitors. Front Oncol. 2019;9:194.","journal-title":"Front Oncol."},{"key":"776_CR11","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/nrc3895","volume":"15","author":"L Yang","year":"2015","unstructured":"Yang L, Rau R, Goodell MA. DNMT3A in haematological malignancies. Nat Rev Cancer. 2015;15:152\u201365 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25693834.","journal-title":"Nat Rev Cancer"},{"key":"776_CR12","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1182\/blood-2013-04-497644","volume":"122","author":"SR Daigle","year":"2013","unstructured":"Daigle SR, Olhava EJ, Therkelsen CA, Basavapathruni A, Jin L, Boriack-Sjodin PA, et al. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood. 2013;122:1017\u201325 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23801631.","journal-title":"Blood"},{"key":"776_CR13","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ccell.2015.06.002","volume":"28","author":"HP Mohammad","year":"2015","unstructured":"Mohammad HP, Smitheman KN, Kamat CD, Soong D, Federowicz KE, Van Aller GS, et al. A DNA hypomethylation signature predicts antitumor activity of LSD1 inhibitors in SCLC. Cancer Cell. 2015;28:57\u201369 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26175415.","journal-title":"Cancer Cell"},{"key":"776_CR14","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1135\/cccc19642060","volume":"29","author":"A\u0160F P\u00edskala","year":"1964","unstructured":"P\u00edskala A\u0160F. Nucleic acids components and their analogues. LI. Synthesis of 1-glycosyl derivatives of 5-azauracil and 5-azacytosine. Coll Czech Chem Commun. 1964;29:2060\u201376.","journal-title":"Coll Czech Chem Commun."},{"key":"776_CR15","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1135\/cccc19642576","volume":"29","author":"J\u0160F Pliml","year":"1964","unstructured":"Pliml J\u0160F. Synthesis of 2\u2032-deoxy-D-ribofuranosyl-5-azacytosine. Coll Czech Chem Commun. 1964;29:2576\u20137.","journal-title":"Coll Czech Chem Commun."},{"key":"776_CR16","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/BF02135399","volume":"20","author":"F \u0160orm","year":"1964","unstructured":"\u0160orm F, P\u00edskala A, \u010cih\u00e1k AVJ. 5-Azacytidine, a new, highly effective cancerostatic. Experientia. 1964;20:202\u20133.","journal-title":"Experientia."},{"key":"776_CR17","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13148-016-0237-y","volume":"8","author":"J Diesch","year":"2016","unstructured":"Diesch J, Zwick A, Garz A-K, Palau A, Buschbeck M, G\u00f6tze KS. A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers. Clin Epigenetics. 2016;8:71 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27330573.","journal-title":"Clin Epigenetics"},{"key":"776_CR18","first-page":"813","volume":"2","author":"J\u010cA Vesel\u00fd","year":"1978","unstructured":"Vesel\u00fd J\u010cA. 5-Azacytidine: mechanism of action and biological effects in mammalian cells. Pharmacol Ther. 1978;2:813\u201340.","journal-title":"Pharmacol Ther."},{"key":"776_CR19","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/0092-8674(80)90237-8","volume":"20","author":"PATS Jones","year":"1980","unstructured":"Jones PATS. Cellular-differentiation, cytidine analogs and DNA methylation. Cell. 1980;20:85\u201393.","journal-title":"Cell."},{"key":"776_CR20","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.3390\/ph3072022","volume":"3","author":"PM Howell","year":"2010","unstructured":"Howell PM, Liu Z, Khong HT. Demethylating agents in the treatment of cancer. Pharmaceuticals (Basel). 2010;3:2022\u201344.","journal-title":"Pharmaceuticals (Basel)."},{"key":"776_CR21","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1200\/JCO.2013.50.3102","volume":"32","author":"T Prebet","year":"2014","unstructured":"Prebet T, Sun Z, Figueroa ME, Ketterling R, Melnick A, Greenberg PL, et al. Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. J Clin Oncol. 2014;32:1242\u20138 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24663049.","journal-title":"J Clin Oncol"},{"key":"776_CR22","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/cmdc.201500394","volume":"11","author":"A Ganesan","year":"2016","unstructured":"Ganesan A. Multitarget drugs: an epigenetic epiphany. ChemMedChem. 2016;11:1227\u201341 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26891251.","journal-title":"ChemMedChem"},{"key":"776_CR23","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1073\/pnas.68.2.378","volume":"68","author":"C Friend","year":"1971","unstructured":"Friend C, Scher W, Holland JG, Sato T. Hemoglobin synthesis in murine virus-induced leukemic cells in vitro: stimulation of erythroid differentiation by dimethyl sulfoxide. Proc Natl Acad Sci U S A. 1971;68:378\u201382.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"776_CR24","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1073\/pnas.73.3.862","volume":"73","author":"RC Reuben","year":"1976","unstructured":"Reuben RC, Wife RL, Breslow R, Rifkind RA, Marks PA. A new group of potent inducers of differentiation in murine erythroleukemia cells. Proc Natl Acad Sci U S A. 1976;73:862\u20136.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"776_CR25","doi-asserted-by":"publisher","first-page":"5705","DOI":"10.1073\/pnas.93.12.5705","volume":"93","author":"VM Richon","year":"1996","unstructured":"Richon VM, Webb Y, Merger R, Sheppard T, Jursic B, Ngo L, et al. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci U S A. 1996;93:5705\u20138.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"776_CR26","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/nbt1272","volume":"25","author":"PA Marks","year":"2007","unstructured":"Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol. 2007;25:84\u201390.","journal-title":"Nat Biotechnol."},{"key":"776_CR27","doi-asserted-by":"crossref","first-page":"22429","DOI":"10.1016\/S0021-9258(18)41547-5","volume":"268","author":"M Kijima","year":"1993","unstructured":"Kijima M, Yoshida M, Sugita K, Horinouchi S, Beppu T. Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. J Biol Chem. 1993;268:22429\u201335.","journal-title":"J Biol Chem."},{"key":"776_CR28","doi-asserted-by":"crossref","first-page":"17174","DOI":"10.1016\/S0021-9258(17)44885-X","volume":"265","author":"M Yoshida","year":"1990","unstructured":"Yoshida M, Kijima M, Akita M, Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem. 1990;265:17174\u20139.","journal-title":"J Biol Chem."},{"key":"776_CR29","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1073\/pnas.95.6.3003","volume":"95","author":"VM Richon","year":"1998","unstructured":"Richon VM, Emiliani S, Verdin E, Webb Y, Breslow R, Rifkind RA, et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci U S A. 1998;95:3003\u20137.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"776_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13148-015-0137-6","volume":"7","author":"A Kumar","year":"2015","unstructured":"Kumar A, Darcis G, Van Lint C, Herbein G. Epigenetic control of HIV-1 post integration latency: implications for therapy. Clin Epigenetics [Internet]. Clinical Epigenetics. 2015;7:1\u201312 Available from: https:\/\/doi.org\/10.1186\/s13148-015-0137-6.","journal-title":"Clinical Epigenetics"},{"key":"776_CR31","doi-asserted-by":"publisher","first-page":"315","DOI":"10.7164\/antibiotics.47.315","volume":"47","author":"H Ueda","year":"1994","unstructured":"Ueda H, Manda T, Matsumoto S, Mukumoto S, Nishigaki F, Kawamura I, et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice. J Antibiot (Tokyo). 1994;47:315\u201323.","journal-title":"J Antibiot (Tokyo)"},{"key":"776_CR32","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1006\/excr.1998.4027","volume":"241","author":"H Nakajima","year":"1998","unstructured":"Nakajima H, Kim YB, Terano H, Yoshida M, Horinouchi S. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res. 1998;241:126\u201333.","journal-title":"Exp Cell Res."},{"key":"776_CR33","doi-asserted-by":"crossref","unstructured":"Ganesan A. Romidepsin and the zinc-binding thiol family of natural product HDAC inhibitors. Fischer J, Childers WE, Ed Success Drug Discov. 2016;","DOI":"10.1002\/9783527800315.ch2"},{"key":"776_CR34","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.critrevonc.2016.07.001","volume":"106","author":"SA Reddy","year":"2016","unstructured":"Reddy SA. Romidepsin for the treatment of relapsed\/refractory cutaneous T-cell lymphoma (mycosis fungoides\/S\u00e9zary syndrome): use in a community setting. Crit Rev Oncol Hematol. 2016;106:99\u2013107 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27637355.","journal-title":"Crit Rev Oncol Hematol"},{"key":"776_CR35","doi-asserted-by":"publisher","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","volume":"117","author":"RL Piekarz","year":"2011","unstructured":"Piekarz RL, Frye R, Prince HM, Kirschbaum MH, Zain J, Allen SL, et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 2011;117:5827\u201334.","journal-title":"Blood."},{"key":"776_CR36","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1042\/BST0320910","volume":"32","author":"CB Yoo","year":"2004","unstructured":"Yoo CB, Cheng JC, Jones PA. Zebularine: a new drug for epigenetic therapy. Biochem Soc Trans. 2004;32:910\u20132.","journal-title":"Biochem Soc Trans."},{"key":"776_CR37","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2174\/15680096113139990077","volume":"13","author":"V Singh","year":"2013","unstructured":"Singh V, Sharma P, Capalash N. DNA methyltransferase-1 inhibitors as epigenetic therapy for cancer. Curr Cancer Drug Targets. 2013;13:379\u201399.","journal-title":"Curr Cancer Drug Targets."},{"key":"776_CR38","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/S1470-2045(17)30576-4","volume":"18","author":"HM Kantarjian","year":"2017","unstructured":"Kantarjian HM, Roboz GJ, Kropf PL, Yee KWL, O\u2019Connell CL, Tibes R, et al. Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1\/2 trial. Lancet Oncol. 2017;18:1317\u201326.","journal-title":"Lancet Oncol."},{"key":"776_CR39","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1177\/1087057111421212","volume":"17","author":"JM Foulks","year":"2012","unstructured":"Foulks JM, Parnell KM, Nix RN, Chau S, Swierczek K, Saunders M, et al. Epigenetic drug discovery: targeting DNA methyltransferases. J Biomol Screen. 2012;17:2\u201317.","journal-title":"J Biomol Screen."},{"key":"776_CR40","doi-asserted-by":"publisher","first-page":"20170069","DOI":"10.1098\/rstb.2017.0069","volume":"373","author":"A Ganesan","year":"2018","unstructured":"Ganesan A. Epigenetic drug discovery: a success story for cofactor interference. Philos Trans R Soc B Biol Sci. 2018;373:20170069.","journal-title":"Philos Trans R Soc B Biol Sci."},{"key":"776_CR41","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ejmech.2018.10.041","volume":"161","author":"A Bouchut","year":"2019","unstructured":"Bouchut A, Rotili D, Pierrot C, Valente S, Lafitte S, Schultz J, et al. Identification of novel quinazoline derivatives as potent antiplasmodial agents. Eur J Med Chem. 2019;161:277\u201391.","journal-title":"Eur J Med Chem."},{"key":"776_CR42","doi-asserted-by":"crossref","unstructured":"Marques-Magalh\u00e3es \u00c2, Gra\u00e7a I, Henrique R, Jer\u00f3nimo C. Targeting DNA methyltranferases in urological tumors. Front Pharmacol. 2018;9.","DOI":"10.3389\/fphar.2018.00366"},{"key":"776_CR43","doi-asserted-by":"publisher","first-page":"4665","DOI":"10.1021\/acs.jmedchem.7b00176","volume":"60","author":"L Halby","year":"2017","unstructured":"Halby L, Menon Y, Rilova E, Pechalrieu D, Masson V, Faux C, et al. Rational design of bisubstrate-type analogues as inhibitors of DNA methyltransferases in cancer cells. J Med Chem. 2017;60:4665\u201379.","journal-title":"J Med Chem."},{"key":"776_CR44","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1158\/1535-7163.MCT-17-0818","volume":"17","author":"MC Manara","year":"2018","unstructured":"Manara MC, Valente S, Cristalli C, Nicoletti G, Landuzzi L, Zwergel C, et al. A quinoline-based DNA methyltransferase inhibitor as a possible adjuvant in osteosarcoma therapy. Mol Cancer Ther. 2018;17:1881\u201392.","journal-title":"Mol Cancer Ther."},{"key":"776_CR45","doi-asserted-by":"publisher","first-page":"282","DOI":"10.2174\/1570180054038413","volume":"2","author":"E Angeles","year":"2005","unstructured":"Angeles E, Hugo Vazquez-Valadez V, Vazquez-Valadez O, Velazquez-Sanchez A, Ramirez A, Martinez L, et al. Computational studies of 1-hydrazinophthalazine (hydralazine) as antineoplasic agent. Docking studies on methyltransferase. Lett Drug Des Discov. 2005;2:282\u20136 Available from: http:\/\/www.eurekaselect.com\/openurl\/content.php?genre=article&issn=1570-1808&volume=2&issue=4&spage=282.","journal-title":"Lett Drug Des Discov"},{"key":"776_CR46","first-page":"4984","volume":"63","author":"A Villar-Garea","year":"2003","unstructured":"Villar-Garea A, Fraga MF, Espada J, Esteller M. Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells. Cancer Res. 2003;63:4984\u20139 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12941824.","journal-title":"Cancer Res"},{"key":"776_CR47","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","volume":"33","author":"OA O\u2019Connor","year":"2015","unstructured":"O\u2019Connor OA, Horwitz S, Masszi T, Van Hoof A, Brown P, Doorduijn J, et al. Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) Study. J Clin Oncol. 2015;33:2492\u20139 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26101246.","journal-title":"J Clin Oncol"},{"key":"776_CR48","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1038\/sj.leu.2403522","volume":"18","author":"S Grant","year":"2004","unstructured":"Grant S. The novel histone deacetylase inhibitor NVP-LAQ824: an addition to the therapeutic armamentarium in leukemia? Leukemia. 2004;18:1931\u20133.","journal-title":"Leukemia."},{"key":"776_CR49","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.3390\/ph3092751","volume":"3","author":"S Subramanian","year":"2010","unstructured":"Subramanian S, Bates SE, Wright JJ, Espinoza-Delgado I, Piekarz RL. Clinical toxicities of histone deacetylase inhibitors. Pharmaceuticals (Basel). 2010;3:2751\u201367.","journal-title":"Pharmaceuticals (Basel)."},{"key":"776_CR50","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13148-017-0319-5","volume":"9","author":"ME Issa","year":"2017","unstructured":"Issa ME, Takhsha FS, Chirumamilla CS, Perez-Novo C, Vanden Berghe W, Cuendet M. Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma. Clin Epigenetics. 2017;9:17.","journal-title":"Clin Epigenetics."},{"key":"776_CR51","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.clml.2018.05.007","volume":"18","author":"JD Cavenagh","year":"2018","unstructured":"Cavenagh JD, Popat R. Optimal management of histone deacetylase inhibitor-related adverse events in patients with multiple myeloma: a focus on panobinostat. Clin Lymphoma Myeloma Leuk. 2018;18:501\u20137 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29804873.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"776_CR52","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.3390\/molecules20033898","volume":"20","author":"M Mottamal","year":"2015","unstructured":"Mottamal M, Zheng S, Huang TL, Wang G. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules. 2015;20:3898\u2013941.","journal-title":"Molecules."},{"key":"776_CR53","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/14712598.2019.1572746","volume":"19","author":"Y Ito","year":"2019","unstructured":"Ito Y, Makita S, Tobinai K. Development of new agents for peripheral T-cell lymphoma. Expert Opin Biol Ther. 2019;19:197\u2013209.","journal-title":"Expert Opin Biol Ther."},{"key":"776_CR54","doi-asserted-by":"publisher","first-page":"185","DOI":"10.5582\/irdr.2016.01024","volume":"5","author":"X Lu","year":"2016","unstructured":"Lu X, Ning Z, Li Z, Cao H, Wang X. Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China. Intractable rare Dis Res. 2016;5:185\u201391.","journal-title":"Intractable rare Dis Res."},{"key":"776_CR55","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/0092-8674(78)90305-7","volume":"14","author":"EP Candido","year":"1978","unstructured":"Candido EP, Reeves R, Davie JR. Sodium butyrate inhibits histone deacetylation in cultured cells. Cell. 1978;14:105\u201313.","journal-title":"Cell."},{"key":"776_CR56","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.lungcan.2004.03.002","volume":"45","author":"T Reid","year":"2004","unstructured":"Reid T, Valone F, Lipera W, Irwin D, Paroly W, Natale R, et al. Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer. Lung Cancer. 2004;45:381\u20136.","journal-title":"Lung Cancer."},{"key":"776_CR57","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.ymgme.2012.08.006","volume":"107","author":"M Mokhtarani","year":"2012","unstructured":"Mokhtarani M, Diaz GA, Rhead W, Lichter-Konecki U, Bartley J, Feigenbaum A, et al. Urinary phenylacetylglutamine as dosing biomarker for patients with urea cycle disorders. Mol Genet Metab. 2012;107:308\u201314.","journal-title":"Mol Genet Metab."},{"key":"776_CR58","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/ana.410030105","volume":"3","author":"RH Mattson","year":"1978","unstructured":"Mattson RH, Cramer JA, Williamson PD, Novelly RA. Valproic acid in epilepsy: clinical and pharmacological effects. Ann Neurol. 1978;3:20\u20135.","journal-title":"Ann Neurol."},{"key":"776_CR59","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1586\/14737140.2014.940329","volume":"14","author":"SA Brodie","year":"2014","unstructured":"Brodie SA, Brandes JC. Could valproic acid be an effective anticancer agent? The evidence so far. Expert Rev Anticancer Ther. 2014;14:1097\u2013100.","journal-title":"Expert Rev Anticancer Ther."},{"key":"776_CR60","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1158\/1078-0432.CCR-16-1729","volume":"23","author":"RM Connolly","year":"2017","unstructured":"Connolly RM, Li H, Jankowitz RC, Zhang Z, Rudek MA, Jeter SC, et al. Combination epigenetic therapy in advanced breast cancer with 5-azacitidine and entinostat: a phase II National Cancer Institute\/Stand Up to Cancer Study. Clin Cancer Res. 2017;23:2691\u2013701.","journal-title":"Clin Cancer Res."},{"key":"776_CR61","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1158\/2159-8290.CD-11-0214","volume":"1","author":"RA Juergens","year":"2011","unstructured":"Juergens RA, Wrangle J, Vendetti FP, Murphy SC, Zhao M, Coleman B, et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov. 2011;1:598\u2013607 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22586682.","journal-title":"Cancer Discov"},{"key":"776_CR62","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.ctrv.2017.03.008","volume":"55","author":"SM Ronnekleiv-Kelly","year":"2017","unstructured":"Ronnekleiv-Kelly SM, Sharma A, Ahuja N. Epigenetic therapy and chemosensitization in solid malignancy. Cancer Treat Rev. 2017;55:200\u20138.","journal-title":"Cancer Treat Rev."},{"key":"776_CR63","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13148-017-0358-y","volume":"9","author":"R Mazzone","year":"2017","unstructured":"Mazzone R, Zwergel C, Mai A, Valente S. Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy. Clin Epigenetics. 2017;9:59 Available from: http:\/\/clinicalepigeneticsjournal.biomedcentral.com\/articles\/10.1186\/s13148-017-0358-y.","journal-title":"Clin Epigenetics"},{"key":"776_CR64","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13148-016-0223-4","volume":"8","author":"L Morera","year":"2016","unstructured":"Morera L, L\u00fcbbert M, Jung M. Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy. Clin Epigenetics. 2016;8:57 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27222667.","journal-title":"Clin Epigenetics"},{"key":"776_CR65","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1021\/jm501234a","volume":"58","author":"H\u00dc Kaniskan","year":"2015","unstructured":"Kaniskan H\u00dc, Konze KD, Jin J. Selective inhibitors of protein methyltransferases. J Med Chem. 2015;58:1596\u2013629.","journal-title":"J Med Chem."},{"key":"776_CR66","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1182\/blood-2017-12-818948","volume":"131","author":"EM Stein","year":"2018","unstructured":"Stein EM, Garcia-Manero G, Rizzieri DA, Tibes R, Berdeja JG, Savona MR, et al. The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. Blood. 2018;131:2661\u20139.","journal-title":"Blood."},{"key":"776_CR67","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1080\/10428194.2018.1430795","volume":"59","author":"N Gulati","year":"2018","unstructured":"Gulati N, B\u00e9guelin W, Giulino-Roth L. Enhancer of zeste homolog 2 (EZH2) inhibitors. Leuk Lymphoma. 2018;59:1574\u201385.","journal-title":"Leuk Lymphoma."},{"key":"776_CR68","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13148-016-0226-1","volume":"8","author":"K Gall Tro\u0161elj","year":"2016","unstructured":"Gall Tro\u0161elj K, Novak Kujundzic R, Ugarkovic D. Polycomb repressive complex\u2019s evolutionary conserved function: the role of EZH2 status and cellular background. Clin Epigenetics. 2016;8:55.","journal-title":"Clin Epigenetics."},{"key":"776_CR69","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/nchembio.1810","volume":"11","author":"E Chan-Penebre","year":"2015","unstructured":"Chan-Penebre E, Kuplast KG, Majer CR, Boriack-Sjodin PA, Wigle TJ, Johnston LD, et al. A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models. Nat Chem Biol. 2015;11:432\u20137.","journal-title":"Nat Chem Biol."},{"key":"776_CR70","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.cbpa.2018.03.003","volume":"45","author":"A-T Hauser","year":"2018","unstructured":"Hauser A-T, Robaa D, Jung M. Epigenetic small molecule modulators of histone and DNA methylation. Curr Opin Chem Biol. 2018;45:73\u201385.","journal-title":"Curr Opin Chem Biol."},{"key":"776_CR71","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.euroneuro.2017.04.003","volume":"27","author":"R Ricken","year":"2017","unstructured":"Ricken R, Ulrich S, Schlattmann P, Adli M. Tranylcypromine in mind (Part II): review of clinical pharmacology and meta-analysis of controlled studies in depression. Eur Neuropsychopharmacol. 2017;27:714\u201331.","journal-title":"Eur Neuropsychopharmacol."},{"key":"776_CR72","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/nm.2661","volume":"18","author":"T Schenk","year":"2012","unstructured":"Schenk T, Chen WC, G\u00f6llner S, Howell L, Jin L, Hebestreit K, et al. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat Med. 2012;18:605\u201311.","journal-title":"Nat Med."},{"key":"776_CR73","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.coph.2015.05.009","volume":"23","author":"T Maes","year":"2015","unstructured":"Maes T, Carceller E, Salas J, Ortega A, Buesa C. Advances in the development of histone lysine demethylase inhibitors. Curr Opin Pharmacol. 2015;23:52\u201360.","journal-title":"Curr Opin Pharmacol."},{"key":"776_CR74","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1111\/cas.13004","volume":"107","author":"S Hino","year":"2016","unstructured":"Hino S, Kohrogi K, Nakao M. Histone demethylase LSD1 controls the phenotypic plasticity of cancer cells. Cancer Sci. 2016;107:1187\u201392.","journal-title":"Cancer Sci."},{"key":"776_CR75","doi-asserted-by":"publisher","first-page":"14773","DOI":"10.1038\/ncomms14773","volume":"8","author":"A Kawamura","year":"2017","unstructured":"Kawamura A, M\u00fcnzel M, Kojima T, Yapp C, Bhushan B, Goto Y, et al. Highly selective inhibition of histone demethylases by de novo macrocyclic peptides. Nat Commun. 2017;8:14773.","journal-title":"Nat Commun."},{"key":"776_CR76","doi-asserted-by":"crossref","unstructured":"Cochran AG, Conery AR, Sims RJ. Bromodomains: a new target class for drug development. Nat Rev Drug Discov. 2019.","DOI":"10.1038\/s41573-019-0030-7"},{"key":"776_CR77","doi-asserted-by":"publisher","first-page":"E5352","DOI":"10.1073\/pnas.1703071114","volume":"114","author":"R Wang","year":"2017","unstructured":"Wang R, Cao X-J, Kulej K, Liu W, Ma T, MacDonald M, et al. Uncovering BRD4 hyperphosphorylation associated with cellular transformation in NUT midline carcinoma. Proc Natl Acad Sci U S A. 2017;114:E5352\u201361.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"776_CR78","doi-asserted-by":"publisher","first-page":"3827","DOI":"10.1021\/jm200108t","volume":"54","author":"C-W Chung","year":"2011","unstructured":"Chung C-W, Coste H, White JH, Mirguet O, Wilde J, Gosmini RL, et al. Discovery and characterization of small molecule inhibitors of the BET family bromodomains. J Med Chem. 2011;54:3827\u201338.","journal-title":"J Med Chem."},{"key":"776_CR79","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ddtec.2016.06.004","volume":"19","author":"G Andrieu","year":"2016","unstructured":"Andrieu G, Belkina AC, Denis GV. Clinical trials for BET inhibitors run ahead of the science. Drug Discov Today Technol. 2016;19:45\u201350.","journal-title":"Drug Discov Today Technol."},{"key":"776_CR80","doi-asserted-by":"publisher","first-page":"11625","DOI":"10.1021\/acs.chemrev.5b00205","volume":"115","author":"G Zhang","year":"2015","unstructured":"Zhang G, Smith SG, Zhou M-M. Discovery of chemical inhibitors of human bromodomains. Chem Rev. 2015;115:11625\u201368.","journal-title":"Chem Rev."},{"key":"776_CR81","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.atherosclerosis.2016.01.036","volume":"247","author":"D Gilham","year":"2016","unstructured":"Gilham D, Wasiak S, Tsujikawa LM, Halliday C, Norek K, Patel RG, et al. RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I\/HDL and represses pathways that contribute to cardiovascular disease. Atherosclerosis. 2016;247:48\u201357.","journal-title":"Atherosclerosis."},{"key":"776_CR82","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1080\/15592294.2017.1322881","volume":"12","author":"M Esteller","year":"2017","unstructured":"Esteller M. Epigenetic drugs: more than meets the eye. Epigenetics. 2017;12:307.","journal-title":"Epigenetics."},{"key":"776_CR83","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/cge.13480","volume":"95","author":"G Velasco","year":"2019","unstructured":"Velasco G, Francastel C. Genetics meets DNA methylation in rare diseases. Clin Genet. 2019;95:210\u201320.","journal-title":"Clin Genet."},{"key":"776_CR84","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/nrg.2016.93","volume":"17","author":"PA Jones","year":"2016","unstructured":"Jones PA, Issa J-PJ, Baylin S. Targeting the cancer epigenome for therapy. Nat Rev Genet. 2016;17:630\u201341 Available from: http:\/\/www.nature.com\/articles\/nrg.2016.93.","journal-title":"Nat Rev Genet"},{"key":"776_CR85","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13148-016-0264-8","volume":"8","author":"I Gra\u00e7a","year":"2016","unstructured":"Gra\u00e7a I, Pereira-Silva E, Henrique R, Packham G, Crabb SJ, Jer\u00f3nimo C. Epigenetic modulators as therapeutic targets in prostate cancer. Clin Epigenetics. 2016;8:98.","journal-title":"Clin Epigenetics."},{"key":"776_CR86","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13148-016-0284-4","volume":"8","author":"RAM Dirks","year":"2016","unstructured":"Dirks RAM, Stunnenberg HG, Marks H. Genome-wide epigenomic profiling for biomarker discovery. Clin Epigenetics. 2016;8:122.","journal-title":"Clin Epigenetics."},{"key":"776_CR87","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13148-016-0244-z","volume":"8","author":"D Weigt","year":"2016","unstructured":"Weigt D, Hopf C, M\u00e9dard G. Studying epigenetic complexes and their inhibitors with the proteomics toolbox. Clin Epigenetics. 2016;8:76.","journal-title":"Clin Epigenetics."},{"key":"776_CR88","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13148-017-0342-6","volume":"9","author":"S Gul","year":"2017","unstructured":"Gul S. Epigenetic assays for chemical biology and drug discovery. Clin Epigenetics. 2017;9:41.","journal-title":"Clin Epigenetics."},{"key":"776_CR89","doi-asserted-by":"crossref","unstructured":"Geel TM, Ruiters MHJ, Cool RH, Halby L, Voshart DC, Andrade Ruiz L, et al. The past and presence of gene targeting: from chemicals and DNA via proteins to RNA. Philos Trans R Soc Lond B Biol Sci. 2018;373.","DOI":"10.1098\/rstb.2017.0077"},{"key":"776_CR90","doi-asserted-by":"publisher","first-page":"12284","DOI":"10.1038\/ncomms12284","volume":"7","author":"D Cano-Rodriguez","year":"2016","unstructured":"Cano-Rodriguez D, Gjaltema RAF, Jilderda LJ, Jellema P, Dokter-Fokkens J, Ruiters MHJ, et al. Writing of H3K4Me3 overcomes epigenetic silencing in a sustained but context-dependent manner. Nat Commun. 2016;7:12284 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27506838.","journal-title":"Nat Commun"},{"key":"776_CR91","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13148-016-0225-2","volume":"8","author":"H Wapenaar","year":"2016","unstructured":"Wapenaar H, Dekker FJ. Histone acetyltransferases: challenges in targeting bi-substrate enzymes. Clin Epigenetics. 2016;8:59.","journal-title":"Clin Epigenetics."},{"key":"776_CR92","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13148-016-0268-4","volume":"8","author":"C Milite","year":"2016","unstructured":"Milite C, Feoli A, Viviano M, Rescigno D, Cianciulli A, Balzano AL, et al. The emerging role of lysine methyltransferase SETD8 in human diseases. Clin Epigenetics. 2016;8:102.","journal-title":"Clin Epigenetics"},{"key":"776_CR93","first-page":"39","volume":"3","author":"P-H Huang","year":"2011","unstructured":"Huang P-H, Plass C, Chen C-S. Effects of histone deacetylase inhibitors on modulating H3K4 methylation marks - a novel cross-talk mechanism between histone-modifying enzymes. Mol Cell Pharmacol. 2011;3:39\u201343 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22468166.","journal-title":"Mol Cell Pharmacol"},{"key":"776_CR94","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1158\/2159-8290.CD-13-0117","volume":"3","author":"T Clozel","year":"2013","unstructured":"Clozel T, Yang S, Elstrom RL, Tam W, Martin P, Kormaksson M, et al. Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. Cancer Discov. 2013;3:1002\u201319.","journal-title":"Cancer Discov."},{"key":"776_CR95","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1038\/s41467-017-01701-2","volume":"8","author":"M Pannek","year":"2017","unstructured":"Pannek M, Simic Z, Fuszard M, Meleshin M, Rotili D, Mai A, et al. Crystal structures of the mitochondrial deacylase Sirtuin 4 reveal isoform-specific acyl recognition and regulation features. Nat Commun. 2017;8:1513.","journal-title":"Nat Commun."},{"key":"776_CR96","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1021\/acs.jmedchem.8b01090","volume":"62","author":"K V\u00f6gerl","year":"2019","unstructured":"V\u00f6gerl K, Ong N, Senger J, Herp D, Schmidtkunz K, Marek M, et al. Synthesis and biological investigation of phenothiazine-based benzhydroxamic acids as selective histone deacetylase 6 inhibitors. J Med Chem. 2019;62:1138\u201366.","journal-title":"J Med Chem."},{"key":"776_CR97","doi-asserted-by":"crossref","unstructured":"Lecointre B, Narozny R, Borrello MT, Senger J, Chakrabarti A, Jung M, et al. Isoform-selective HDAC1\/6\/8 inhibitors with an imidazo-ketopiperazine cap containing stereochemical diversity. Philos Trans R Soc Lond B Biol Sci. 2018:373.","DOI":"10.1098\/rstb.2017.0364"},{"key":"776_CR98","doi-asserted-by":"publisher","first-page":"14836","DOI":"10.1002\/anie.201709050","volume":"56","author":"N Rajabi","year":"2017","unstructured":"Rajabi N, Auth M, Troelsen KR, Pannek M, Bhatt DP, Fontenas M, et al. Mechanism-based inhibitors of the human Sirtuin 5 deacylase: structure-activity relationship, biostructural, and kinetic insight. Angew Chem Int Ed Engl. 2017;56:14836\u201341.","journal-title":"Angew Chem Int Ed Engl."},{"key":"776_CR99","doi-asserted-by":"crossref","unstructured":"de Lera AR, Ganesan A. Epigenetic polypharmacology: from combination therapy to multitargeted drugs. Clin Epigenetics. 8:105 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27752293.","DOI":"10.1186\/s13148-016-0271-9"},{"key":"776_CR100","doi-asserted-by":"publisher","first-page":"e1342748","DOI":"10.1080\/23723556.2017.1342748","volume":"4","author":"ES Jos\u00e9-En\u00e9riz","year":"2017","unstructured":"Jos\u00e9-En\u00e9riz ES, Rabal O, Agirre X, Oyarzabal J, Prosper F. Dual epigenetic modifiers for cancer therapy. Mol Cell Oncol. 2017;4:e1342748.","journal-title":"Mol Cell Oncol."},{"key":"776_CR101","doi-asserted-by":"publisher","first-page":"E1072","DOI":"10.1073\/pnas.1319122111","volume":"111","author":"C Das","year":"2014","unstructured":"Das C, Roy S, Namjoshi S, Malarkey CS, Jones DNM, Kutateladze TG, et al. Binding of the histone chaperone ASF1 to the CBP bromodomain promotes histone acetylation. Proc Natl Acad Sci U S A. 2014;111:E1072\u201381 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24616510.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"776_CR102","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/nature05287","volume":"444","author":"J Huang","year":"2006","unstructured":"Huang J, Perez-Burgos L, Placek BJ, Sengupta R, Richter M, Dorsey JA, et al. Repression of p53 activity by Smyd2-mediated methylation. Nature. 2006;444:629\u201332 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17108971.","journal-title":"Nature"},{"key":"776_CR103","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1021\/jm500843d","volume":"58","author":"A Erdmann","year":"2015","unstructured":"Erdmann A, Halby L, Fahy J, Arimondo PB. Targeting DNA methylation with small molecules: what\u2019s next? J Med Chem. 2015;58:2569\u201383.","journal-title":"J Med Chem."},{"key":"776_CR104","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1002\/prot.24830","volume":"83","author":"A Cabaye","year":"2015","unstructured":"Cabaye A, Nguyen KT, Liu L, Pande V, Schapira M. Structural diversity of the epigenetics pocketome. Proteins. 2015;83:1316\u201326 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25974248.","journal-title":"Proteins"},{"key":"776_CR105","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.chembiol.2015.05.009","volume":"22","author":"J Lu","year":"2015","unstructured":"Lu J, Qian Y, Altieri M, Dong H, Wang J, Raina K, et al. Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4. Chem Biol. 2015;22:755\u201363 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26051217.","journal-title":"Chem Biol"},{"key":"776_CR106","doi-asserted-by":"publisher","first-page":"7124","DOI":"10.1073\/pnas.1521738113","volume":"113","author":"K Raina","year":"2016","unstructured":"Raina K, Lu J, Qian Y, Altieri M, Gordon D, Rossi AMK, et al. PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer. Proc Natl Acad Sci U S A. 2016;113:7124\u20139 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27274052.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"776_CR107","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.ccr.2011.12.029","volume":"21","author":"H-C Tsai","year":"2012","unstructured":"Tsai H-C, Li H, Van Neste L, Cai Y, Robert C, Rassool FV, et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell. 2012;21:430\u201346 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22439938.","journal-title":"Cancer Cell"},{"key":"776_CR108","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1248\/bpb.29.234","volume":"29","author":"T Maeda","year":"2006","unstructured":"Maeda T, Wakasawa T, Shima Y, Tsuboi I, Aizawa S, Tamai I. Role of polyamines derived from arginine in differentiation and proliferation of human blood cells. Biol Pharm Bull. 2006;29:234\u20139 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16462024.","journal-title":"Biol Pharm Bull"},{"key":"776_CR109","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1172\/JCI69736","volume":"124","author":"N Ahuja","year":"2014","unstructured":"Ahuja N, Easwaran H, Baylin SB. Harnessing the potential of epigenetic therapy to target solid tumors. J Clin Invest. 2014;124:56\u201363.","journal-title":"J Clin Invest."},{"key":"776_CR110","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.gde.2011.01.022","volume":"21","author":"G Li","year":"2011","unstructured":"Li G, Reinberg D. Chromatin higher-order structures and gene regulation. Curr Opin Genet Dev. 2011;21:175\u201386 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21342762.","journal-title":"Curr Opin Genet Dev"},{"key":"776_CR111","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.molcel.2011.08.018","volume":"43","author":"KC Wang","year":"2011","unstructured":"Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. Mol Cell. 2011;43:904\u201314 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21925379.","journal-title":"Mol Cell"},{"issue":"1748","key":"776_CR112","doi-asserted-by":"publisher","first-page":"20170074","DOI":"10.1098\/rstb.2017.0074","volume":"373","author":"David J. Hanly","year":"2018","unstructured":"Hanly DJ, Esteller M, Berdasco M. Interplay between long non-coding RNAs and epigenetic machinery: emerging targets in cancer? Philos Trans R Soc Lond B Biol Sci. 2018;373 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29685978.","journal-title":"Philosophical Transactions of the Royal Society B: Biological Sciences"},{"key":"776_CR113","doi-asserted-by":"publisher","first-page":"4456","DOI":"10.1093\/nar\/gky171","volume":"46","author":"T Mlambo","year":"2018","unstructured":"Mlambo T, Nitsch S, Hildenbeutel M, Romito M, M\u00fcller M, Bossen C, et al. Designer epigenome modifiers enable robust and sustained gene silencing in clinically relevant human cells. Nucleic Acids Res. 2018;46:4456\u201368.","journal-title":"Nucleic Acids Res."},{"key":"776_CR114","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/nyas.12356","volume":"1309","author":"S Wee","year":"2014","unstructured":"Wee S, Dhanak D, Li H, Armstrong SA, Copeland RA, Sims R, et al. Targeting epigenetic regulators for cancer therapy. Ann N Y Acad Sci. 2014;1309:30\u20136.","journal-title":"Ann N Y Acad Sci."},{"key":"776_CR115","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2217\/epi.14.73","volume":"7","author":"Y-Y Juo","year":"2015","unstructured":"Juo Y-Y, Gong X-J, Mishra A, Cui X, Baylin SB, Azad NS, et al. Epigenetic therapy for solid tumors: from bench science to clinical trials. Epigenomics. 2015;7:215\u201335.","journal-title":"Epigenomics."},{"key":"776_CR116","doi-asserted-by":"publisher","first-page":"4780","DOI":"10.1021\/acs.jmedchem.6b01595","volume":"60","author":"GS Hailu","year":"2017","unstructured":"Hailu GS, Robaa D, Forgione M, Sippl W, Rotili D, Mai A. Lysine deacetylase inhibitors in parasites: past, present, and future perspectives. J Med Chem. 2017;60:4780\u2013804.","journal-title":"J Med Chem."},{"key":"776_CR117","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/ng.620","volume":"42","author":"G Nikoloski","year":"2010","unstructured":"Nikoloski G, Langemeijer SMC, Kuiper RP, Knops R, Massop M, T\u00f6nnissen ERLTM, et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet. 2010;42:665\u20137.","journal-title":"Nat Genet."},{"issue":"19","key":"776_CR118","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1056\/NEJM200011093431901","volume":"343","author":"Manel Esteller","year":"2000","unstructured":"Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, OF H, Vanaclocha V, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med, Available from. 2000;343:1350\u20134 http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11070098.","journal-title":"New England Journal of Medicine"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-019-0776-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13148-019-0776-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-019-0776-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T22:33:00Z","timestamp":1612909980000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalepigeneticsjournal.biomedcentral.com\/articles\/10.1186\/s13148-019-0776-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":118,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["776"],"URL":"https:\/\/doi.org\/10.1186\/s13148-019-0776-0","relation":{},"ISSN":["1868-7075","1868-7083"],"issn-type":[{"value":"1868-7075","type":"print"},{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"29 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"174"}}